Definition

A micelle nanoparticle formulation composed of the Toll-Like receptor 7 (TLR7) agonist phospholipid conjugate 1v270 encapsulated within 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE)-polyethylene glycol (PEG)-2000, with potential immunostimulating activity. Upon intravenous administration of the nanoparticles encapsulating TLR7 agonist 1v270 MBS8, the TLR7 agonist targets, binds to and activates TLR7, thereby stimulating dendritic cells (DCs) and neutrophils, and enhancing natural killer cell (NK) cytotoxicity. This activation results in the production of pro-inflammatory cytokines, including interferon alpha. MBS8 may activate cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune responses leading to tumor cell lysis. In addition, MBS8 is able to stimulate immune memory T cells to further recognize and eliminate cancer cells. TLR7 is a member of the TLR family, which plays a fundamental role in pathogen recognition and the activation of innate immunity. The micelle formulation was engineered to reduce systemic cytokine production which may lower systemic toxicity.